Deutsch
 
Benutzerhandbuch Datenschutzhinweis Impressum Kontakt
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas

MPG-Autoren
/persons/resource/persons127670

Auer,  Matthias K.
Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80539

Stalla,  Günter K.
Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons172989

Stieg,  Mareike R.
Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)

art%3A10.1007%2Fs11102-016-0726-1.pdf
(beliebiger Volltext), 432KB

Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Auer, M. K., Stalla, G. K., & Stieg, M. R. (2016). Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. PITUITARY, 19(5), 461-471. doi:10.1007/s11102-016-0726-1.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-002C-4C8B-E
Zusammenfassung
Non-alcoholic fatty liver disease (NAFLD) is a hallmark of the metabolic syndrome and has been shown to be an independent predictor of cardiovascular mortality. Although glucocorticoids and growth hormone are known to be implicated in its pathophysiology, it has only rarely been investigated in the context of patients with pituitary insufficiency or former cortisol excess. Case-control study in patients with biochemically controlled Cushing's disease (CD; N = 33) and non-functioning pituitary adenomas (NFPA; N = 79). NAFLD was estimated by calculating the fatty liver index (FLI) including BMI, waist circumference, GGT and triglyceride levels. Although there was no difference in FLI between patients with NFPA and CD, we identified average daily hydrocortisone (HC) intake in those with adrenal insufficiency to be an independent predictor of FLI (beta = 1.124; p = 0.017), even after adjusting for BMI and waist circumference. In line, those with a FLI > 60 were also taking in average significantly more HC per day than those with a score < 60 (21.05 mg +/- 5.9 vs. 17.9 mg +/- 4.4; p = 0.01). FLI was also the best independent predictor for HbA1c and fasting glucose levels (both p = 0.001). Growth hormone deficiency and replacement therapy were not associated with FLI in either group. While HC dosage affects FLI as an estimate of NFLD in patients with CD and NFPA, the benefit of GH replacement still needs to be determined. In contrast to reports in CD patients with active disease, NAFLD in those with biochemical control was not different from NFPA patients.